Millions of Americans on Medicare are asking the same question: does Medicare cover Ozempic, Wegovy, or the new [Foundayo (orforglipron) full review](/health/foundayo-review-2026-orforglipron (Foundayo) review-glp1-pill/) pill in 2026? The short answer is: it depends — and the rules just changed significantly.
Here's everything you need to know, including the new $50/month Medicare program launching July 1, 2026.
The Basic Rule: Indication Determines Coverage
Medicare's coverage of GLP-1 drugs like Ozempic has always hinged on why the drug is prescribed, not what it is. The Social Security Act historically prohibited Medicare from covering drugs used solely for weight loss — and that restriction still applies in most cases.
- Medicare Part D covers Ozempic if prescribed for Type 2 diabetes
- Medicare does NOT cover Ozempic if prescribed for weight loss only
- Wegovy (same drug, higher dose) has limited Medicare coverage — only for cardiovascular risk reduction in patients with established heart disease
- A new Medicare Bridge program launches July 1, 2026 that changes everything for Foundayo and Wegovy
Which GLP-1 Drugs Does Medicare Cover in 2026?
Ozempic (semaglutide injection): Yes — if prescribed for Type 2 diabetes. Most Part D plans cover it. If your doctor prescribes it for weight loss only, it won't be covered. Average cost after coverage: varies by plan, but the 2026 out-of-pocket cap of $2,100 under the Inflation Reduction Act means you'll pay $0 for covered drugs once you hit that limit.
Mounjaro (tirzepatide injection): Yes — over 90% of Part D plans cover it for Type 2 diabetes. Same rule applies: diabetes diagnosis required for coverage. Not covered for weight loss alone.
Wegovy (semaglutide, weight-loss dose): Limited. Medicare only covers Wegovy for patients who are overweight or obese and have documented cardiovascular disease. This is a narrow window — not everyone qualifies.
Zepbound (tirzepatide for weight): Limited. Covered by some plans for obesity-related obstructive sleep apnea. Not covered for weight loss alone.
Foundayo (orforglipron oral pill): Starting July 1, 2026, covered under the new Medicare GLP-1 Bridge program for $50/month.
The Big Change: Medicare's GLP-1 Bridge Program
On December 23, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a major policy shift: the Medicare GLP-1 Bridge Program, launching July 1, 2026.
The Bridge program covers:
- Foundayo (orforglipron, all formulations) — the first oral GLP-1 weight-loss pill
- Wegovy (all formulations)
- Zepbound KwikPen formulation
This is a major win for seniors. Wegovy's list price is over $1,300/month. Getting it for $50 is a game-changer — but only if you meet the eligibility criteria and your plan participates.
Looking further ahead: CMS also announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a 5-year innovation model that expands GLP-1 coverage through Medicaid starting May 2026 and through Medicare Part D in January 2027. States must opt in to the Medicaid portion.
What About Medicaid?
Medicaid coverage is a patchwork. Only about 13 state Medicaid programs covered GLP-1s for obesity under fee-for-service as of early 2026 — and several states have recently cut coverage:
- Pennsylvania ended adult coverage effective January 1, 2026
- California eliminated GLP-1 weight-loss coverage
- Michigan restricted coverage of several drugs
- North Carolina briefly eliminated, then reinstated coverage in December 2025
If you're on Medicaid, contact your state program or a benefits counselor directly — the rules vary dramatically by state.
How Much Does Ozempic Cost on Medicare?
If Ozempic is covered under your Part D plan for your diabetes diagnosis, your actual cost depends on your plan's formulary tier. With the IRA's $2,100 out-of-pocket cap, even expensive drugs become more affordable later in the year.
Workarounds If You're Not Covered
Manufacturer savings cards are the most commonly used option — but there's a critical catch: Medicare, Medicaid, VA, and TRICARE beneficiaries cannot use manufacturer savings cards by law. This is a hard federal restriction that trips up many seniors.
Here's what Medicare beneficiaries can do:
1. Get prescribed for a covered indication. If you have Type 2 diabetes, Ozempic and Mounjaro may be covered under your diabetes diagnosis. Talk to your doctor about whether that's accurate for your situation.
2. Qualify under the cardiovascular disease indication. If you're overweight or obese and have documented heart disease or stroke history, you may qualify for Medicare-covered Wegovy under the CVD indication.
3. Wait for the Bridge program. If you can wait until July 1, 2026, the $50/month Bridge program for Foundayo and Wegovy may be an option.
4. Explore the BALANCE Model (2027). The full Medicare Part D expansion under the BALANCE model goes live January 2027.
5. Appeal a denial. If Medicare denies coverage, you have the right to appeal. A doctor's documentation of medical necessity can sometimes change outcomes.
6. GoodRx for self-pay. If you're paying cash, GoodRx and similar discount services can reduce Ozempic's cost — though it won't approach the $25/month savings-card pricing available to those with private insurance.
Foundayo: The New Option Worth Knowing About
FDA-approved on April 1, 2026, Foundayo (orforglipron) is the first GLP-1 weight-loss drug available as an oral pill — no injections, no food or water restrictions, just a daily tablet. About 400,000 Americans are already using it.
For Medicare beneficiaries, Foundayo is significant because it's one of the three drugs covered under the July 2026 Bridge program at $50/month. For commercially insured patients, the Eli Lilly savings card brings it down to $25/month. Self-pay starts at $149/month for the lowest dose.
- First oral GLP-1 — no injections needed
- No food or water restrictions (unlike Rybelsus/Ozempic)
- $50/month under Medicare Bridge starting July 2026
- $149/month self-pay (lowest dose) — cheaper than Wegovy self-pay
- Brand new drug — less long-term safety data than semaglutide
- Medicare Bridge requires prior authorization
- Not all Medicare plans participating in Bridge program
- Commercially insured savings card not available to Medicare beneficiaries
Bottom Line
Medicare's GLP-1 coverage is evolving fast. Here's the quick summary:
- Ozempic for diabetes: Covered by most Part D plans right now
- Wegovy/Zepbound/Foundayo for weight loss: Not covered until July 1, 2026 (Bridge program)
- Bridge program ($50/month): Foundayo, Wegovy, Zepbound — launches July 1, 2026
- Manufacturer savings cards: Not available to Medicare/Medicaid beneficiaries
- Out-of-pocket cap: $2,100/year under the IRA — then $0 for covered drugs
If you're a Medicare beneficiary trying to access GLP-1 drugs for weight management, the Bridge program launching July 1 is the biggest near-term opportunity. Talk to your doctor now to prepare your prior authorization paperwork so you're ready to enroll when it opens.
For the latest plan-specific details, visit Medicare.gov's drug coverage finder or call 1-800-MEDICARE.
